RESEARCH ARTICLE

Distribution and Role of N-acetyltransferase 2 Genetic Polymorphisms in Bladder Cancer Risk in a Lebanese Population

Rami Nasr¹, Sally Temraz², Deborah Mukherji², Ali Shamseddine², Reem Akika³, Sehrish Abbasi³, Raja Khali³, Muhammad Bulbul¹, Hani Tamim⁴, Nathalie K Zgheib³*

Abstract

Background: In Lebanon, bladder cancer (BC) has an unusually high prevalence. Individuals who are exposed to aromatic amines from smoking or certain occupations and carrying the slow N-acetyl transferase 2 (NAT2) acetylator phenotype may be at a higher risk.

Methods: Data and DNA from 115 Lebanese BC cases and 306 controls were examined. Ten NAT2 single nucleotide polymorphisms were genotyped, seven of which were then included in haplotype and phenotype analysis.

Results: BC patients were more likely to be males (87.8% vs. 54.9%) and current smokers (60.9% vs. 26.5%) when compared to controls. In both groups, most participants had the slow NAT2 acetylator phenotype (66.1% of BC cases vs 62.7% of controls; P=0.302) with the NAT2*5B and *6A haplotypes being the most common. The odds ratio (95%CI) of having BC among slow NAT2 acetylators was 1.157 (0.738-1.815) and remained non-significant after adjustment [1.097 (0.666-1.806)]. Sensitivity analysis with a subgroup of 113 cases and 84 controls for which occupational history was available revealed a statistically significant association between slow NAT2 acetylators and BC in females only. The sample size was however very small and the CI quite wide.

Conclusions: This is the first study to evaluate the distribution of NAT2 haplotypes and their potential role in BC in a Lebanese population. The absence of any significant association may be due to the relatively small sample size, the unavailability of matching by gender, and the lack of evaluation of genetic interactions with extent of active and passive smoking, exposure to environmental pollutants, diet, and other genes. The potential association limited to females needs further evaluation.

Keywords: NAT2- bladder cancer- Lebanese

Asian Pac J Cancer Prev, 18 (9), 2561-2568

Introduction

According to Globocan data from 2012 (www.globocan.iarc.fr), bladder cancer (BC) is the 9th most common cancer worldwide comprising 3.1% of all cases. In Lebanon, BC appears to have an unusually high prevalence. Data for the period of 2003 to 2008 revealed BC to be the second most common after prostate cancer in males with an incidence rate of 34 per 100,000. Although the rate was much lower in females (9 per 100,000), it is alarming that the calculated annual percent changes were on the rise from 2003 to 2008, and the projected rates for 2018 are even higher in both males (41.2 per 100,000) and females (13.4 per 100,000) (Shamseddine et al., 2014). These trends may be attributed to increased exposure to a variety of environmental and occupational carcinogens including the commensurate increase in tobacco smoking (Dhaini and Koeiissi, 2014; Baris et al., 2009; IARC monograph 100E-6, 2013; Jaafar et al., 2014; Malats and Real, 2015; Sauter G, 2014; Sibai et al., 2016).

It is known that many of the carcinogens require metabolic activation in order to induce their toxic effect; therefore, it is supposed that genetic typing of the relevant drug metabolizing enzymes (DMEs) may explain some of the variability in the cancer process. According to the International Agency for Research on Cancer (IARC), there are at least 62 carcinogens in cigarette smoke with polycyclic aromatic hydrocarbons (PAHs), aromatic amines and N-nitroso compounds being highly toxic to the urothelium (IARC monograph 100E-6, 2013). In the liver, these compounds are activated by cytochrome P450 (CYP450) into reactive metabolites that may be further activated by O-acetylation via the N-acetyltransferase 1 (NAT1) enzyme in the urothelium. Carcinogens and

¹Division of Urology, Department of Surgery, ²Division of Hematology and Oncology, Department of Internal Medicine, ³Department of Pharmacology and Toxicology, ⁴Department of Internal Medicine and Clinical Research Institute, Faculty of Medicine, American University of Beirut, Beirut, Lebanon. *For Correspondence: nk16@aub.edu.lb
their metabolites are inactivated by hepatic Phase II enzymes such as glutathione S-transferases (GST) and N-acetyltransferase 2 (NAT2) (Antonova et al., 2015; Tsukino et al., 2004). Accordingly, it has been postulated that subjects who carry CYP450 and NAT1 genetic polymorphisms that lead to an increased enzymatic activity, and those with GSTT1 and GSTM1 null genotypes or NAT2 haplotypes that confer the slow acetylator phenotype are at a higher risk of developing BC (Cascorbi et al., 2001; Fontana et al., 2009; McGrath et al., 2006; Song et al., 2009). Results have shown that the interaction between smoking and genetic polymorphisms of DMEs is strongest with GSTM1 null and slow NAT2 acetylators (Antonova et al., 2015; Garcia-Closas et al., 2005; McGrath et al., 2006; Osviannikov et al., 2012; Rouissi et al., 2009; Yuan et al., 2008), with the NAT2 association being the most consistent (Moore et al., 2011; Tsukino et al., 2004) as has been shown in 3 recent meta-analyses asserting its role in BC (An et al., 2015; Wu et al., 2016; Zhu et al., 2015). Additional sources of the carcinogenic aromatic amines include a number of occupations many of which have been linked to an increased risk of bladder cancer (Dhaini and Kobeissi, 2014; Malats and Real, 2015; Sauter G, 2014), especially among slow NAT2 acetylators (Covolo et al., 2008; Osviannikov et al., 2012; Yuan et al., 2008).

To date, a large number of NAT2 single nucleotide polymorphisms (SNPs) have been reported with 107 documented haplotypes (Boukouvala, 2016; Walker et al., 2009). Studies in Middle Eastern Arabs showed a high prevalence of NAT2*5 and NAT2*6 alleles and a higher frequency of slow acetylators in comparison to other ethnicities (Bu et al., 2004; Hamdy et al., 2003; Sabbaghi et al., 2008; Tanira et al., 2003). To our knowledge, no data are available on the potential association of NAT2 genetic polymorphisms with BC in Arabs including the Lebanese except for one study by El-Desoky et al., (2005) who evaluated 3 common NAT2 SNPs and documented haplotypes (Boukouvala S, 2016; Walker et al., 2009) using only 7 of the 107 SNPs as the other 3 were all wild type. NAT2*4 is the reference haplotype and corresponds to rapid NAT2 acetylation activity were categorized as fast acetylators, those who had one of each were categorized as intermediate acetylators (Boukouvala S, 2016; Walker et al., 2009) using only 7 of the 107 SNPs as the other 3 were all wild type. NAT2*4 is the reference haplotype and corresponds to rapid NAT2 acetylation activity. Subjects who had a combination of 2 haplotypes corresponding to rapid NAT2 acetylation activity were categorized as fast acetylators, those who had one of each were categorized as intermediate acetylators (Boukouvala S, 2016; Walker et al., 2009; Cascorbi et al., 1995; Cascorbi et al., 2001) (Table 2).

Materials and Methods

Study population

This is a case-control association study. It includes 115 Lebanese subjects who were diagnosed with transitional cell carcinoma (TCC) of the bladder -of which 41.1% were invasive- and who were admitted for treatment at the American University of Beirut Medical Center (AUBMC) between 2012 and 2016. Controls included 84 patients who presented during the same recruitment period to the urology clinics or service for other complaints in addition to 222 historic controls who did not have BC but were previously recruited for a separate study (Esmerian et al., 2011). Peripheral whole blood was drawn and stored at -80°C. A questionnaire was administered. Due to insufficient numbers or missing data for most of the risk factors, only current smoking (defined as being a cigarette smoker at the time of diagnosis for BC cases, and at the time of recruitment for controls) and alcohol intake were analyzed. Occupational history was available for 113 of the 115 cases and the 84 controls. No such data were available for the 222 historic controls. Medical chart review was performed for TCC histologic diagnosis.

The study was approved by the Institutional Review Board (IRB), and all subjects signed an informed consent.

NAT2 analysis

DNA was isolated from 300 microliters of peripheral blood using the Flexigene DNA isolation kit (Qiagen, CA, USA) as per manufacturer’s guidelines and stored at -20°C until analysis.

Genotyping for ten SNPs in an 866 bp fragment spanning the coding region of NAT2 was performed using restriction fragment length polymorphism (RFLP) technique as described by Deitz et al. (2000). The 3 primer pairs (5’-GGCTATAAAGAACTCTAGGAAC-3’ with 5’-AAGGGTTTATTTTGGTCTCTTATATTATAAT-3’, the initial PCR, 5’-CACCTTCTCCTCAGTGACCG-3’ with 5’-TGTCAGCAGAAATGCAGGACGC-3’ for the nested PCR1, 5’-AGAGGTCTTTCAGTGAAGTCTGCT-3’ with 5’-AAGGGTTTATTTTGGTCTCTTATATTATAAT-3’ for the nested A803G PCR) were purchased from Thermo Fisher (Germany) and the 1X RedTaq ready mix per reaction mix containing Taq polymerase and dNTPs was purchased from Sigma-Aldrich (MO, USA). FastDigest restriction enzymes (Thermo Scientific, MA, USA) were used for SNP detection as such: FokI for C282T; MspI and KpnI combined for G191A, A434C, and C481T; TaqI and BamHI combined for T111C, G590A, C759T, and G857A; and Accl and Ddel for T341C and A803G on nested PCR respectively. Digested products were run on 3% agarose gel (PeqLab, Germany) containing 0.025% ethidium bromide (Amresco, Ohio, USA) for 1 hour and visualized using a Gel Doc instrument (Biorad, CA, USA).

NAT2 haplotypes and their corresponding phenotypes were assigned based on the NAT2 haplotype nomenclature (Boukouvala S, 2016; Walker et al., 2009) using only seven SNPs as the other 3 were all wild type. NAT2*4 is the reference haplotype and corresponds to rapid NAT2 activity (Table 1). Subjects who had a combination of 2 haplotypes corresponding to rapid NAT2 acetylation activity were categorized as fast acetylators, those who had a combination of 2 haplotypes corresponding to slow NAT2 activity were categorized as slow acetylators, and those who had one of each were categorized as intermediate acetylators (Boukouvala, 2016; Walker et al., 2009; Cascorbi et al., 1995; Cascorbi et al., 2001) (Table 2).

Statistical analysis

Data were entered into SPSS v.23.0 (IBM, USA). Minor allele frequencies (MAF) of the NAT2 SNPs were
calculated and tested for Hardy Weinberg Equilibrium (HWE) using chi-square test. Baseline demographic data of cases and controls including age, sex, current smoking and alcohol intake were computed and compared using Student t-test, chi-square test and logistic regression as applicable. Comparisons of NAT2 phenotypes between cases and controls were performed using chi-square test and logistic regression. Sensitivity analysis with the subgroup for which occupational history was available was attempted. Occupational exposure to aromatic amines included having any of the following occupations: hairdressers, paint industry, printing ink industry, rubber and cable manufacture, textile and leather works, truck or bus drivers, roofers, chimney sweeps, truck drivers, tar and asphalt workers, brickyard workers, aluminum industry, gas industries and blacksmiths. Univariate and multivariate logistic regressions were also performed to include statistically significant confounders as applicable. Despite the small sample size, analyses were run on the whole sample and after stratification for sex, current smoking and occupational exposure to aromatic amines as these are established risk factors for BC. P values of 0.05 or less and odds ratios (ORs) with 95% confidence intervals (CIs) that did not include the value of 1 were considered statistically significant.

Results

The tested NAT2 alleles were all in HWE. The major haplotypes in controls were NAT2*5B (40.68%), *6A (30.89%), *4 (20.27%) and *7B (3.43%) (Table 1), and genotypes were NAT2*5B/*6A (23.9%), *5B/*5B (38.69%), and *6A/*6A (11.4%) in this order (Table 2). In both groups, the majority of participants had the slow NAT2 acetylator phenotype (66.1% in BC cases vs 62.7% in controls; P=0.302). BC patients were more likely to be males (87.8% vs. 54.9%), current smokers (60.9% vs. 26.5%) and alcohol drinkers (46.1% vs. 28.8%). There was no difference in mean age between cases and controls (64.89± 10.57 vs. 66.92 ± 15.14) (Table 3). The odds ratio of having BC among slow NAT2 acetylators was 1.157 (95%CI: 0.738-1.815) and remained non-significant even after adjusting for sex, current smoking and alcohol intake [1.097 (95%CI: 0.666-1.806)]. Stratification analysis revealed higher odds of having BC in men (OR was 1.75; 95%CI: 1.07-2.88) and in those with higher occupational exposure to aromatic amines.

Table 1. NAT2 Genetic Polymorphisms in Bladder Cancer Cases and Controls with Designation of Haplotypes

| Allele | Phenotype | N (%)| Cases | Controls |
|--------|-----------|------|-------|----------|
| *4¹ | Rapid | 42 (18.26) | 124 (20.27) |
| *5A | Slow | 77 (33.48) | 189 (30.89) |
| *5B | Slow | 90 (39.13) | 249 (40.68) |
| *5C | Slow | 6 (2.61) | 16 (2.61) |
| *6A | Slow | 77 (33.48) | 189 (30.89) |
| *6B | Slow | 1 (0.44) | 0 |
| *6C | Slow | 0 |
| *7B | Slow | 11 (4.78) | 21 (3.43) |
| *12A | Rapid | 3 (1.30) | 3 (0.48) |
| *12C | Rapid | 3 (1.30) | 3 (0.48) |
| *13 | Rapid | 3 (1.30) | 3 (0.48) |
| *14B | Slow | 0 |
| *14D | Slow | 1 (0.44) | 0 |

Cases MAF¹ (%) | 0.43 | 40 | 41.3 | 39.13 | 49.67 | 41.3 | 4.78
Controls MAF² (%) | 0.16 | 34.97 | 44.28 | 42.16 | 31.05 | 44.12 | 3.43

¹ Wild type; ² Minor Allele Frequency

Figure 1. Association between NAT2 Phenotype (Slow vs. Fast and Intermediate) and Bladder Cancer Risk in the Whole Sample and Stratified by Sex, Smoking and Occupational Exposure to Aromatic Amines². Sex and/or smoking, and alcohol intake as applicable. Data were available for a subgroup of 113 cases and 84 controls. Occupational exposure included those who had any of the following occupations: Hairdressers, paint industry, printing ink industry, rubber and cable manufacture, textile and leather works, truck or bus drivers, roofers, chimney sweeps, truck drivers, tar and asphalt workers, brickyard workers, aluminum industry, gas industries and blacksmiths.

DOI:10.22034/APJCP.2017.18.9.2561
NAT2 and Bladder Cancer in the Lebanese

Asian Pacific Journal of Cancer Prevention, Vol 18 2563
Table 2. Distribution of NAT2 Genotypes and Phenotypes Among Bladder Cancer Cases and Controls

| NAT2        | Cases N=115 | Controls N=306 |
|-------------|-------------|---------------|
| Rapid acetylators |             |               |
| *A/*A        | 6 (5.2)     | 16 (5.2)      |
| *A/*E        | 4 (3.5)     | 14 (4.6)      |
| *A/*12C      | 0 (1.0)     | 1 (0.3)       |
| *A/*13       | 2 (1.7)     | 1 (0.3)       |
| Intermediate acetylators |         |               |
| *A/*5A       | 17 (14.8)   | 45 (14.7)     |
| *A/*5B       | 7 (6.1)     | 37 (12.1)     |
| *A/*6A       | 0 (1.0)     | 1 (0.3)       |
| *A/*7B       | 3 (2.6)     | 5 (1.6)       |
| *A/*14D      | 1 (0.9)     | 0             |
| *A/*13       | 1 (0.9)     | 0             |
| Slow acetylators |           |               |
| *A/*A        | 76 (66.1)   | 192 (62.7)    |
| *A/*5B       | 14 (12.2)   | 58 (19.0)     |
| *A/*5C       | 2 (1.7)     | 4 (1.3)       |
| *A/*6A       | 37 (32.2)   | 73 (23.9)     |
| *A/*7B       | 1 (0.9)     | 0             |
| *A/*7B       | 3 (2.6)     | 5 (1.6)       |
| *A/*14B      | 0 (1.0)     | 1 (0.3)       |
| *A/*13       | 1 (0.9)     | 0             |

Discussion

This is the first study to evaluate the distribution of NAT2 haplotypes and their potential role in BC in the Lebanese population. The MAFs and frequencies of the corresponding NAT2 haplotypes, genotypes and phenotypes were similar to Europeans (Walker et al., 2009; Cascorbi et al., 1995; Sabbagh et al., 2008) and Arabs (Bu et al., 2004; Hamdy et al., 2003; Tanira et al., 2009; Woolhouse et al., 1997) with the NAT2*5B and *6A haplotypes that correlate with slow NAT2 enzyme activity being the most common. As expected, results revealed that males, current smokers, alcohol drinkers and those who have occupational history of exposure to aromatic amines were at a higher risk for having BC (Covolo et al., 2008; Cui et al., 2013; Hosen et al., 2015; Klimcakova et al., 2011; Kobeissi, Yassine, Jabbour, Moussa, and Dhaini, 2013; Lubin et al., 2007; Lu, Chung, Huang, and Ko, 2005; Marcus et al., 2000; Ouerhani et al., 2009; Tao et al., 2010). Nevertheless, the risk was the same irrespective of the NAT2 acetylator status. Of note is that the potential association between slow NAT2 acetylator status and BC in females only may be due to mere chance and needs further evaluation, as this was shown in the sensitivity analysis only with a much smaller sample size and a very wide CI. In addition, knowing that smoking habits and occupational risks differ by gender, it would have been preferable to match cases and controls for gender especially that application of logistic regression cannot fully correct this bias.

The lack of association between NAT2 genetic polymorphisms and BC risk may be mostly attributed to the relatively small sample size knowing that, from 2 recent meta-analyses, the NAT2 slow acetylation status only modestly increases the risk of BC [OR(95%CI): 1.31 (1.11-1.55)] (An et al., 2015; Zhu et al., 2015). It is interesting however that although few of the “negative” association studies were based on small numbers of cases and controls (Wu et al., 2016; Zupa et al., 2009), several did not show any associations despite evaluating a very large population. This is shown by the study of
Table 3. Comparison between Bladder Cancer Cases and Control

|                          | Cases (N=115) | Controls (N=306) | P¹ | OR (95%CI)   |
|--------------------------|---------------|------------------|----|-------------|
| Age (years)              | 64.89 ± 10.57 | 66.92 ± 15.14    | 0.186 | 0.990 (0.975-1.005) |
| Sex                      |               |                  |     |             |
| Female                   | N (%)         |                  |     |             |
| Male                     | N (%)         |                  |     |             |
| Current smoking          |               |                  |     |             |
| No                       | N (%)         |                  |     |             |
| Yes                      | N (%)         |                  |     |             |
| Current alcohol intake   |               |                  |     |             |
| No                       | N (%)         |                  |     |             |
| Yes                      | N (%)         |                  |     |             |
| Occupational exposure to aromatic amines¹ | No | N (%) | 65 (57.5) | 61 (72.6) | 0.029 | 1.959 (1.067-3.596) |
| Fast                     | N (%)         |                  |     |             |
| Slow                     | N (%)         |                  |     |             |
| NAT2 phenotype 1         |               |                  |     |             |
| Intermediate             | N (%)         |                  |     |             |
| Slow                     | N (%)         |                  |     |             | 0.786 | 1.056 (0.398-2.799) |
| Fast & Intermediate      | N (%)         |                  |     |             |
| Slow                     | N (%)         |                  |     |             |

¹ Student-t test or chi-square as applicable; ² Data were available for a subgroup of 113 cases and 84 controls. The Yes category included those who had any of the following occupations: hairdressers, paint industry, printing ink industry, rubber and cable manufacture, textile and leather works, truck or bus drivers, roofers, chimney sweeps, truck drivers, tar and asphalt workers, brickyard workers, aluminum industry, gas industries and blacksmiths.

Garcia-Glosas et al., (2005) where the odd (95%CI) of BC was 1.37 (0.94-1.99) in a population of 783 cases and 703 controls. It appears that the gene-environment interaction between NAT2 and smoking plays a major role in the increased risk, especially the cumulative exposure to cigarette smoke over time. For instance, Moore et al., (2011) reported that NAT2 slow acetylation is not associated with BC risk (OR; 95%CI) among never (1.04; 0.71-1.51), former (0.95; 0.75-1.20), or current smokers (1.33, 0.91-1.95). However a relationship emerged when smoking intensity was evaluated. Among slow acetylators who ever smoked at least 40 cigarettes/day, risk was elevated among ever (1.82; 1.14-2.91, P<0.07) and current heavy smokers (3.16; 1.22-8.19, P=0.03) compared to rapid acetylators in each category. Similar positive associations were found with various categorizations of smoking intensity such as among those who smoke at least 20 pack-years (Ouerhani et al., 2009), 25 pack-years (Tsukino et al., 2004), 28 pack-years (Gu et al., 2005), and 37.4 pack-years (Cui et al., 2013). Interestingly, environmental tobacco smoke coming from smoking by household members, co-workers and parents during childhood was found to be associated with an increased risk of BC among slow NAT2 acetylators (Tao et al., 2010). In our study, we were unfortunately not able to evaluate the extent of active smoking in pack-years, and did not collect data on passive smoking. In addition, although we specifically inquired about narghile (waterpipe) smoking and categorized it as smoking, it is possible that some participants considered it as a mild and non-harmful habit and hence did not report it (Nakkash and Khalil, 2010; Nakkash, 2011). To our knowledge, no study specifically evaluated the role of NAT2 polymorphisms in narghile smoking, an area where we believe further research is warranted. Another confounding factor is the potentially protective role of NAT2 slow acetylators with the Mediterranean diet that is especially rich in cruciferous vegetables (Lin et al., 2009). Other emerging factors of potential research interest are the exposure to increasing levels of environmental air pollutants from vehicular and generator emission (Farah et al., 2014). Finally, it may be relevant to genotype for additional genes of interest and evaluate not only gene-environment interactions, but also gene-gene interactions such as that between NAT2 and GST (Brockmöller et al., 1996; Rouissi et al., 2009; Yuan et al., 2008).

In conclusion, this is the first study to evaluate the distribution of NAT2 haplotypes and their potential role in BC in a Lebanese population. The absence of association between NAT2 acetylation status and BC risk may be due to the relatively small sample size and the unavailability of matching of cases and controls by gender, as well as the lack of evaluation of genetic interactions with extent of active and passive smoking, environmental pollutants, diet, and other genes. Further studies are needed to elucidate the factors behind the increasing prevalence of BC in Lebanon.

Acknowledgments

Lebanese National Council for Scientific Research (LNCSR) funding to N. K. Zghieb.

References

An Y, Li H, Wang KJ, et al (2015). Meta-analysis of the relationship between slow acetylation of N-acetyl transferase 2 and the risk of bladder cancer. Genet Mol Res, 14, 16896-904.

Antonova O, Toncheva D, Grigorov E (2015). Bladder cancer risk from the perspective of genetic polymorphisms in the carcinogen metabolizing enzymes. J BUON, 20, 1397-406.

Baris D, Karagas MR, Verrill C, et al (2009). A case-control study of smoking and bladder cancer risk: emergent patterns over time. J Natl Cancer Inst, 101, 1553-61.
Basma HA, Kobeissi LH, Jabbour ME, Moussa MA, Dhaini HR (2013). CYP2E1 and NQO1 genotypes and bladder cancer risk in a Lebanese population. *Int J Mol Epidemiol Genet*, 4, 207-17.

Boukouvala S (2016). Human NAT2 alleles (Haplotypes). http://nat.mbg.duth.gr/Human%20NAT2%20alleles_2013.htm [Electronic version].

Brockmöller J, Cascorbi I, Kerb R, Roots I (1996). Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. *Cancer Res*, 56, 3915-25.

Bu R, Gutierrez MI, Al-Rasheed M, Belgaumia N, Bhatia K (2004). Variable drug metabolism genes in Arab population. *Pharmacogenomics J*, 4, 260-6.

Cascorbi I, Drakoulis N, Brockmöller J, et al (1995). Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. *Am Hum Genet*, 57, 581-92.

Cascorbi I, Roots I, Brockmöller J (2001). Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. *Cancer Res*, 61, 5051-6.

Covolo L, Placidi D, Gelatti U, et al (2008). Bladder cancer, GSTs, NAT1, NAT2, SULT1A1, XRC1, XRC3, XPD genetic polymorphisms and coffee consumption: a case-control study. *Eur J Epidemiol*, 23, 355-62.

Cui X, Lu X, Hiura M, et al (2013). Association of genotypes of carcinogen-metabolizing enzymes and smoking status with bladder cancer in a Japanese population. *Environ Health Prev Med*, 18, 136-42.

Deitz AC, Zheng W, Lef MA, et al (2000). N-Acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women. *Cancer Epidemiol Biomarkers Prev*, 9, 905-10.

Dhaini HR, Kobeissi L (2014). Toxicogenetic profile and cancer risk: a case-series meta-analysis of a gene-environment interaction. *Cancer Epidemiol Biomarkers Prev*, 9, 461-7.

Edesoky ES, Abdelsalam YM, Salama RH, et al (2005). NAT2*5*/5* genotype (341T>C) is a potential risk factor for schistosomiasis-associated bladder cancer in Egyptians. *Ther Drug Monit*, 27, 297-304.

Esmerian MO, Mirit Z, Habbal MZ, et al (2011). Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people. *Cancer Epidemiol Biomarkers Prev*, 9, 180-9.

Farah W, Nakhl MB, Abboud M, et al (2014). Time series analysis of air pollutants in Beirut, Lebanon. *Environ Monit Assess*, 186, 8203-13.

Fontana L, Delort L, Joumard L, et al (2009). Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort. *Anticancer Res*, 29, 1631-4.

Garcia-Clossas M, Malats N, Silverman D, et al (2005). NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish bladder cancer study and meta-analyses. *Lancet*, 366, 649-63.

Gu J, Liang D, Wang Y, Lu C, Wu X (2005). Effects of N-acetyltransferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. *Mutat Res*, 581, 97-104.

Hamdy SI, Hiratsuka M, Narahara K, et al (2003). Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. *Br J Clin Pharmacol*, 55, 560-9.

Hosen MB, Islam J, Salam MA, et al (2015). N-acetyltransferase 2 gene polymorphism as a biomarker for susceptibility to bladder cancer in Bangladeshi population. *Asia Pac J Clin Oncol*, 11, 78-84.

IARC monograph 100E-6 (2013). Tobacco smoking. http://monographs.iarc.fr/ENG/Monographs/vol100E/mono100E-6.pdf [Electronic version].

Jaafer M, Baalbaki R, Mrad R, et al (2014). Dust episodes in Beirut and their effect on the chemical composition of coarse and fine particulate matter. *Sci Total Environ*, 496, 75-83.

Klimcakova L, Habalova V, Sivonova M, et al (2011). Effect of NAT2 gene polymorphism on bladder cancer risk in Slovak population. *Mol Biol Rep*, 38, 1287-93.

Kobeissi LH, Yassine IA, Jabbour ME, Moussa MA, Dhaini HR (2013). Urinary bladder cancer risk factors: a Lebanese case-control study. *Asian Pac J Cancer Prev*, 14, 3205-11.

Lin J, Kamat A, Gu J, et al (2009). Dietary intake of vegetables and fruits and the modification effects of GSTM1 and NAT2 genotypes on bladder cancer risk. *Cancer Epidemiol Biomarkers Prev*, 18, 2090-7.

Lu CM, Chung MC, Huang CH, Ko YC (2005). Interaction effect in bladder cancer between N-acetyltransferase 2 genotype and alcohol drinking. *Urol Int*, 75, 360-4.

Lubin JH, Kogevinas M, Silverman D, et al (2007). Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish bladder cancer study. *Int J Epidemiol*, 36, 236-41.

Malats N, Real FX (2015). Epidemiology of bladder cancer. *Hematol Oncol Clin North Am*, 29, 177-89.

Marcus PM, Hayes RB, Vineis P, et al (2000). Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. *Cancer Epidemiol Biomarkers Prev*, 9, 461-7.

McGrath M, Michaud D, De VL (2006). Polymorphisms in GSTT1, GSTM1 and NAT2 genes and bladder cancer risk in men and women. *BMC Cancer*, 6, 239.

Moore LE, Baris DR, FigueroaJD, et al (2011). GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis. *Carcinogenesis*, 32, 182-9.

Nakkash R, Khalil J (2010). Health warning labelling practices on narghile (shisha, hookah) waterpipe tobacco products and related accessories. *Tob Control*, 19, 235-9.

Nakkash RT, Khalil J, Affif RA (2011). The rise in narghile (shisha, hookah) waterpipe tobacco smoking: a qualitative study of perceptions of smokers and non-smokers. *BMC Public Health*, 11, 315.

Ouherhani S, Rouissi K, Marrakchi R, et al (2009). Combined effect of NAT2, MTR and MTHFR genotypes and tobacco on bladder cancer susceptibility in Tunisian population. *Cancer Detect Prev*, 32, 395-402.

Ovsiannikov D, Selinski S, Lehmml ML, et al (2012). Polymorphic enzymes, urinary bladder cancer risk, and structural change in the local industry. *J Toxicol Environ Health A*, 75, 557-65.

Rouissi K, Ouherhani S, Marrakchi R, et al (2009). Combined effect of smoking and inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 on bladder cancer in a Tunisian population. *Cancer Genet Cyto genet*, 190, 101-7.

Sabbagh A, Langaney A, Darl P, et al (2008). Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. *BMC Genet*, 9, 21.

Sauter G (2014). Bladder cancer. In: Stewart B W and Wild C P (Eds.), International Agency for Research on Cancer (IARC) (pp. 444-452). Lyon, France.

Shamsedine A, Saleh A, Charafe-jeddi M, et al (2014). Cancer trends in Lebanon: a review of incidence rates for the period
of 2003-2008 and projections until 2018. *Popul Health Metr.,* 12, 4.

Sibai AM, Iskandarani M, Darzi A, et al (2016). Cigarette smoking in a Middle Eastern country and its association with hospitalisation use: a nationwide cross-sectional study. *BMJ Open,* 6, e009881.

Song BK, Xing DL, Zhang LR, et al (2009). Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in central China. *Cancer Detect Prev,* 32, 416-23.

Tanira MO, Simsek M, Al BK, et al (2003). Distribution of arylamine N-acetyltransferase 2 (nat2) genotypes among Omanis. *J Sci Res Med Sci,* 5, 9-14.

Tao L, Xiang YB, Wang R, et al (2010). Environmental tobacco smoke in relation to bladder cancer risk--the Shanghai bladder cancer study [corrected]. *Cancer Epidemiol Biomarkers Prev,* 19, 3057-65.

Tsukino H, Nakao H, Kuroda Y, et al (2004). Glutathione S-transferase (GST) M1, T1 and N-acetyltransferase 2 (NAT2) polymorphisms and urothelial cancer risk with tobacco smoking. *Eur J Cancer Prev,* 13, 509-14.

Walker K, Ginsberg G, Hattis D, et al (2009). Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity. *J Toxicol Environ. Health B Crit Rev,* 12, 440-72.

Woolhouse NM, Qureshi MM, Bastaki SM, et al (1997). Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis. *J Pharmacogenetics,* 7, 73-82.

Wu P, Wang X, Zhang L, Mo N, Lv Z (2016). Association between N-acetyltransferase 2 polymorphism and bladder cancer risk: Results from studies of the past decade and a meta-analysis. *Clin Genitourin Cancer,* 14, 122-9.

Yuan JM, Chan KK, Coetzee GA, et al (2008). Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer. *Carcinogenesis,* 29, 1386-93.

Zhu Z, Zhang J, Jiang W, et al (2015). Risks on N-acetyltransferase 2 and bladder cancer: a meta-analysis. *Onco Targets Ther,* 8, 3715-20.

Zupa A, Sgambato A, Bianchino G, et al (2009). GSTM1 and NAT2 polymorphisms and colon, lung and bladder cancer risk: a case-control study. *Anticancer Res,* 29, 1709-14.

---

**Supplementary Table 1. Association between NAT2 Phenotype (Slow vs. Fast and Intermediate) and Bladder Cancer Risk**

| Case-Control | OR (95%CI) Unadjusted | OR (95%CI) Adjusted¹ |
|--------------|------------------------|---------------------|
|              | Fast and Intermediate  | Slow                | Fast and Intermediate  | Slow                |
| Total sample | 1.157 (0.738-1.815)    | 1                   | 1.097 (0.666-1.806)    |
| Stratified by sex |                     |                     |                      |
| Female       | 0.326 (0.103-1.025)    | 1                   | 0.356 (0.106-1.198)    |
| Male         | 1.420 (0.837-2.410)    | 1                   | 1.416 (0.810-2.476)    |
| Stratified by current smoking |                 |                     |                      |
| No           | 0.828 (0.429-1.595)    | 1                   | 0.821 (0.414-1.626)    |
| Yes          | 1.688 (0.859-3.316)    | 1                   | 1.491 (0.728-3.053)    |

¹Sex and/or smoking and alcohol intake as applicable

---

**Supplementary Table 2. Association between NAT2 Phenotype (Slow vs. Fast vs. Intermediate) and Bladder Cancer Risk**

| Case-Control | OR (95%CI) Unadjusted | OR (95%CI) Adjusted¹ |
|--------------|------------------------|---------------------|
|              | Fast and Intermediate  | Slow                | Fast and Intermediate  | Slow                |
| Total sample | 0.898 (0.325-2.485)    | 1.056 (0.398-2.799)  | 1.084 (0.297-2.687)    | 0.997 (0.348-2.858)  |
| Stratified by sex |                     |                     |                      |
| Female       | 0.870 (0.089-8.455)    | 0.287 (0.028-2.949)  | 0.887 (0.084-9.358)    | 0.320 (0.028-3.615)  |
| Male         | 1.058 (0.332-3.373)    | 1.488 (0.496-4.465)  | 0.831 (0.245-2.818)    | 1.214 (0.382-3.855)  |
| Stratified by current smoking |                 |                     |                      |
| No           | 0.414 (0.123-1.393)    | 0.410 (0.132-1.273)  | 0.525 (0.148-1.867)    | 0.495 (0.151-1.622)  |
| Yes          | 3.448 (0.374-31.792)   | 5.213 (0.587-46.299) | 3.917 (0.399-38.404)   | 5.140 (0.547-48.289) |

¹Sex and/or smoking and alcohol intake as applicable
### Supplementary Table 3. Comparison between Bladder Cancer Cases and Controls in the Subgroup with Available Occupational History of Exposure to Aromatic Amines

|                      | Cases (N=113) | Controls (N=84) | P¹         |
|----------------------|--------------|----------------|------------|
| **Age (years)**      |              |                |            |
|                      | Mean ± SD    |                |            |
|                      | 64.63 ± 10.48| 66.89 ± 19.12  | 0.289      |
| **Sex**              |              |                |            |
| Male                 | N (%)        |                |            |
|                      | 99 (87.6)    | 49 (58.3)      |            |
| Female               | N (%)        |                |            |
|                      | 14 (12.4)    | 35 (41.7)      | <0.001     |
| **Current smoking**  |              |                |            |
| Yes                  | N (%)        |                |            |
|                      | 70 (61.9)    | 33 (39.3)      | 0.002      |
| No                   | N (%)        |                |            |
|                      | 43 (38.1)    | 51 (60.7)      |            |
| **Current alcohol intake** |          |                |            |
| Yes                  | N (%)        |                |            |
|                      | 53 (46.9)    | 30 (35.7)      |            |
| No                   | N (%)        |                |            |
|                      | 60 (53.1)    | 54 (64.3)      | 0.145      |
| **Occupational exposure to aromatic amines²** | |                |            |
| Yes                  | N (%)        |                |            |
|                      | 48 (42.5)    | 23 (27.4)      |            |
| No                   | N (%)        |                |            |
|                      | 65 (57.5)    | 61 (72.6)      | 0.029      |
| **NAT2 phenotype 1** |              |                |            |
| Fast                 | N (%)        |                |            |
|                      | 6 (5.3)      | 4 (4.8)        |            |
| Intermediate         | N (%)        |                |            |
|                      | 33 (29.2)    | 23 (27.4)      |            |
| Slow                 | N (%)        |                |            |
|                      | 74 (65.5)    | 57 (67.9)      | 0.939      |
| **NAT2 phenotype 2** |              |                |            |
| Fast & Intermediate  | N (%)        |                |            |
|                      | 39 (34.5)    | 27 (32.1)      |            |
| Slow                 | N (%)        |                |            |
|                      | 74 (65.5)    | 57 (67.9)      | 0.727      |

¹ Student-t test or chi-square as applicable; ² The Yes category included those who had any of the following occupations: hairdressers, paint industry, printing ink industry, rubber and cable manufacture, textile and leather works, truck or bus drivers, roofers, chimney sweeps, truck drivers, tar and asphalt workers, brickyard workers, aluminum industry, gas industries and blacksmiths.

### Supplementary Table 4. Association between NAT2 Phenotype (Slow vs. Fast and Intermediate) and Bladder Cancer Risk in the Subgroup with Available Occupational History of Exposure to Aromatic Amines

|                      | Unadjusted | Adjusted¹ |
|----------------------|------------|-----------|
|                      | OR (95%CI) | OR (95%CI) | OR (95%CI) | OR (95%CI) |
|                      | OR (95%CI) | Slow      | Fast and Intermediate | Slow |
| **Cases**            |            |           |               |            |
| Total sample         | 113        | 1         | 1.113 (0.611-2.027) | 1.381 (0.713-2.676) |
| Stratified by sex    |            |           |               |            |
| Female               | 14         | 1         | 3.927 (1.064-14.490) | 5.180 (1.169-22.947) |
| Male                 | 99         | 1         | 0.897 (0.430-1.870)  | 0.961 (0.453-2.040) |
| Stratified by current smoking | | | | |
| No                   | 43         | 1         | 1.575 (0.675-3.673)  | 1.881 (0.740-4.784) |
| Yes                  | 70         | 1         | 0.857 (0.353-2.079)  | 0.982 (0.385-2.507) |
| Stratified by occupational exposure | | | | |
| No                   | 65         | 1         | 1.115 (0.537-2.313)  | 1.305 (0.585-2.913) |
| Yes                  | 48         | 1         | 1.288 (0.423-3.920)  | 1.447 (0.436-4.799) |

¹Sex and/or smoking and/or occupational exposure and alcohol intake as applicable

### Supplementary Table 5. Association between NAT2 Phenotype (Slow vs. Fast vs. Intermediate) and Bladder Cancer Risk in the Subgroup with Available Occupational History of Exposure to Aromatic Amines

|                      | Unadjusted | Adjusted¹ |
|----------------------|------------|-----------|
|                      | OR (95%CI) | OR (95%CI) | OR (95%CI) | OR (95%CI) |
|                      | OR (95%CI) | Slow      | Fast          | Intermediate | Slow |
| **Cases**            |            |           |               |               |            |
| Total sample         | 113        | 1         | 1.155 (0.311-4.288) | 1.105 (0.586-2.085) | 1.573 (0.367-6.728) | 1.350 (0.671-2.714) |
| Stratified by sex    |            |           |               |               |            |
| Female               | 14         | 1         | 2.400 (0.181-31.883) | 4.267 (1.101-16.537) | 2.729 (0.183-40.793) | 6.195 (1.221-31.423) |
| Male                 | 99         | 1         | 1.196 (0.220-6.489)  | 0.854 (0.394-1.853)  | 1.373 (0.238-7.917)  | 0.901 (0.405-2.005) |
| Stratified by current smoking | | | | | |
| No                   | 43         | 1         | 3.500 (0.628-19.512) | 1.300 (0.522-3.239)  | 4.338 (0.644-29.210) | 1.540 (0.562-4.219) |
| Yes                  | 70         | 1         | 0.224 (0.019-2.608)  | 0.998 (0.392-2.538)  | 0.198 (0.014-2.872)  | 1.155 (0.431-3.098) |
| Stratified by occupational exposure | | | | | |
| No                   | 65         | 1         | 1.463 (0.232-9.228)  | 1.078 (0.505-2.302)  | 3.209 (0.425-24.225) | 1.170 (0.509-2.692) |
| Yes                  | 48         | 1         | 0.773 (0.118-5.076)  | 1.545 (0.432-5.225)  | 0.648 (0.082-5.152)  | 1.952 (0.470-8.015) |

¹Sex and/or smoking and/or occupational exposure and alcohol intake as applicable